A new scoring system called Cognivue Amyloid Risk Measure (CARM) uses a computerized test to estimate the risk of cerebral amyloid deposition, assisting in identifying Alzheimer's disease-related cognitive impairment. The tool was developed and validated in older adults and is integrated into the Cognivue Clarity system, enabling its use in primary care settings without access to advanced diagnostic tools. The CARM may aid in reducing unnecessary referrals, prioritizing patients for amyloid-lowering therapy, and facilitating decisions around confirmatory testing and treatment referrals.

Source: Neurology and Therapy, Cognivue Press